Daly City, CA, United States of America

Evan Lewis



Average Co-Inventor Count = 9.0

ph-index = 2

Forward Citations = 24(Granted Patents)


Company Filing History:


Years Active: 2008-2011

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Evan Lewis

Introduction

Evan Lewis is a notable inventor based in Daly City, CA (US). He has made significant contributions to the field of therapeutic agents, particularly through his innovative work on enzyme-cleavable prodrug compounds. With a total of 2 patents, his inventions are paving the way for advancements in medical treatments.

Latest Patents

Evan Lewis's latest patents focus on enzyme-cleavable prodrug compounds. The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group, and, optionally, a linker group. This prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Additionally, the patents disclose methods of designing prodrugs by utilizing TOP-cleavable sequences within the conjugate and methods of treating patients with these innovative prodrugs.

Career Highlights

Throughout his career, Evan Lewis has worked with prominent companies in the pharmaceutical industry, including Medarex Inc. and Coulter Pharmaceutical, Inc. His experience in these organizations has contributed to his expertise in developing therapeutic solutions.

Collaborations

Evan has collaborated with several professionals in his field, including Vincent Dubois and Ann Marie Fernandez. These collaborations have likely enriched his work and led to further innovations in his projects.

Conclusion

Evan Lewis is a distinguished inventor whose work on enzyme-cleavable prodrug compounds is making a significant impact in the medical field. His contributions and collaborations highlight the importance of innovation in developing effective therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…